Frontier    

Focus    

Frontier  

Focus      

Professional 

Professional

• Completed Angel and Pre-A financing rounds
• Out-licensed two assets

• Series B funding
• Completed Phase I dose escalations of LB1410 and LB4330
• Recognized as“Specialized, high-end and innovation-driven SMEs”
•  2 patents granted in China, 4 patents granted through PCT

• Out-licensed one project
• Recognized as a “High-Tech Enterprise” by the local government
• Received funding support from the “Scientific Innovation Plan of Action” of Shanghai
• Received special government subsidies for equity financing
• VP Dr. Luan was awarded the honorary title of “Leading Talent of Minhang District”
• One patent granted

• Completed Series A funding
• Received FDA IND clearance for LB1410

• Received NMPA IND clearance for the combination therapy (LB1410 + LB4330)
• Initiated Phase I expansion studies for LB1410 and LB4330
• Re-recognized as a “High-Tech Enterprise”
• The CEO was selected as a “Scientific and Technological Leading Talent of the Wujiang Economic-Technological Development Zone”

• Completed Pre-A+ financing round
• Out-licensed three projects
• Received funding support from the “Scientific Innovation Plan of Action” of Shanghai
• The CEO was recognized as a “Special Expert of Shanghai Municipality”
• One patent granted

• Received NMPA IND clearance for LB1410
• Received FDA and NMPA IND clearance for LB4330
• Initiated Phase I clinical trials for LB1410 and LB4330
• Received three funding grants
• Three patents granted
• Received support from local government authorities

• LB1410 Phase I completed with efficacy expansion study ongoing
• LB4330 Phase I completed
• LB1410 + LB4330 combination in Phase Ib/II clinical trials
• LB1410 in Phase II/III clinical trial